Finerenone Besylate is an oral, nonsteroidal mineralocorticoid receptor antagonist indicated for the treatment of chronic kidney disease associated with type 2 diabetes to reduce the risk of cardiovascular… Read more
Finerenone Besylate is an oral, nonsteroidal mineralocorticoid receptor antagonist indicated for the treatment of chronic kidney disease associated with type 2 diabetes to reduce the risk of cardiovascular events. By selectively blocking aldosterone receptors in the heart and kidneys, this medication offers a distinct mechanism of action compared to steroidal alternatives. To support rigorous quality control and pharmaceutical analysis, our inventory provides essential reference standards for the Finerenone Besylate active pharmaceutical ingredient, alongside related impurities, metabolites, and stable isotope labelled compounds. These high-quality materials are critical for accurate impurity profiling, method validation, and routine analytical testing. By utilizing these precise standards, laboratories can ensure the integrity of their assay procedures, maintain regulatory compliance, and consistently monitor the purity and stability of pharmaceutical formulations throughout the development and manufacturing lifecycle.